number of companies and university teams are racing to produce genetic therapies for sickle cell disease. Because the inherited disorder is caused by a single mutation, it’s long been seen as one of the easier potential targets for gene-based treatments, and the advent of CRISPR gene-editing technology has energized the pursuit.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.